chevron_leftBack
As of 24 April 2025, Mezzion Pharma Co.,Ltd. has a market cap of $816.31M USD, ranking #9183 globally and #215 in South Korea. It ranks #891 in the Healthcare sector, and #48 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$816.31MUSD
1.17T KRW
Enterprise Value
$801.98MUSD
1.14T KRW
Revenue (TTM)
$6.0MUSD
8.61B KRW
EBITDA (TTM)
-$9.35MUSD
-13.34B KRW
Net Income (TTM)
-$13.57MUSD
-19.48B KRW
EBITDA Margin
-155%
Profit Margin
-226%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Dong-Hyun Park
open_in_new
Employees
17
Founded
2002
Website
mezzion.co.kr
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.8% | 21% | 35% | 27% | 33% | 7.1% |
Upcoming Earnings
Earnings Date
Thu, May 15
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
140410
(주)메지온
ISIN: KR7140410002
Shares Out.:
Shares Outstanding:
30.007M1
Shares Float:
21.469M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
38.35K KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Mezzion Pharma Co.,Ltd.
Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.
